EndoPredict Publications

First prospective outcome data for the second-generation multigene test EndoPredict in ER positive/HER2 negative breast cancer.

Ettl J, Anders KS, Hapfelmeier A, Paepke S, Noske A, Weichert W, Klein E, Kiechle M.

Arch Gynecol Obstet 2020 [Epub ahead of print]

https://link.springer.com/article/10.1007%2Fs00404-020-05771-4

Prognostic value of EndoPredict in women with hormone receptor-positive, HER2-negative invasive lobular breast cancer.

Sestak I, Filipits M, Buus R, Rudas M, Balic M, Knauer M, Kronenwett R, Fitzal F, Cuzick J, Gnant M, Greil R, Dowsett M, Dubsky P.

Clin Cancer Res 26(17):4682-4687, 2020

https://pubmed.ncbi.nlm.nih.gov/32561662/

Individualized chemotherapy benefit prediction by EndoPredict in patients with early breast cancer in an Indian cohort.

Somashekhar SP, Zaveri S, Vijay DG, Dattatreya PS, Kuman R, Islahi F, Bahl C.

Journal of Clinical Oncology Global Oncology. 6:1363-1369, 2020

https://pubmed.ncbi.nlm.nih.gov/32897733/

The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.

Dubsky PC, Singer CF, Egle D, Wette V, Petru E, Balic M, Pichler A, Greil R, Petzer AL, Bago-Horvath Z, Fesl C, Meek SM, Kronenwett R, Rudas M, Gnant M, and Filipits on behalf of the Austrian Breast Colorectal Cancer Study Group.

European Journal of Cancer 134:99-106, 2020

https://www.ejcancer.com/article/S0959-8049(20)30223-9/fulltext

EndoPredict in early hormone receptor-positive, HER2-negative breast cancer.

Almstedt K, Mendoza S, Otto M, Battista MJ, Steetskamp J, Heimes AS, Krajnak S, Poplawski A, Gerhold-Ay A, Hasenburg A, Denkert C, Schmidt M.

Breast Cancer Res Treat. 182:237-146, 2020

https://link.springer.com/article/10.1007/s10549-020-05688-1

Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests.

Jahn SW, Bosl A, Tsybrovskyy O, Gruber-Rossipal C, Helfgott R, Fitzal F, Knauer M, Balic M, Jasarevic Z, Offner F, Moinfar F.

Br J Cancer 122:1744-1746, 2020

https://www.nature.com/articles/s41416-020-0838-2

Change in therapeutic management after the EndoPredict assay in a prospective decision impact study of mexican premenopausal breast cancer patients.

Villareal-Garza C, Lopez-Martinez EA, Deneken-Hernandez Z, Maffuz-Aziz A, Munoz-Lozano JF, Barragan-Carrillo R, Ramos-Elias P, Moreno B, Diaz-Perez H, Pena-Curiel O, Curiel-Valdez, JdJ, Bautista-Pina V.

PLoS One. 15(3):e0228884, 2020

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0228884

Retrospective cost-analysis of the EndoPredict test in patients with primary breast cancer in a German breast center.

Neusser S, Philipp L, Schlake G, Neumann A, Tonnies P, Wilhelms S, Petry C, Kronenwett R, Wasem J, Schlake W, Biermann-Stallwitz J

Journal of Public Health: From Theory to Practice 2020

https://link.springer.com/article/10.1007/s10389-020-01193-3

Evaluation of the 12-Gene molecular score and the 21-gene recurrence score as predictors of response to neo-adjuvant chemotherapy in estrogen receptor-positive, HER2-negative breast cancer.

Soliman H, Wagner S, Flake DD, Robson M, Schwartzberg L, Sharma P, Magliocco A, Kronenwett R, Lancaster JM, Lanchbury JS, Gutin A, Gradishar W.

Annals of Surgical Oncology. 27(3):765-771, 2020

https://link.springer.com/article/10.1245%2Fs10434-019-08039-7

Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EPclin) use (UCBG 2-14).

Penault-Llorca F, Kwiatkowski F, Arnaud A, Levy C, Leheurteur M, Uwer L, Derbel O, Le Rol A, Jacquin JP, Jouannaud C, Quenel-Tueux N, Girre V, Foa C, Guardiola E, Lortholary A, Catala S, Guiu S, Valent A, Boinon D, Lemonnier J, Delaloge S.

Breast. 49:132-40, 2020

https://www.sciencedirect.com/science/article/pii/S0960977619305843?via%3Dihub

Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results.

Noske A, Anders SI, Ettl J, Hapfelmeier A, Steiger K, Specht K, Weichert W, Kiechle M, Klein E.

Breast. 2020; 49:101-7. [In Progress]

https://www.sciencedirect.com/journal/the-breast/vol/49/suppl/C

Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results.

Noske A, Anders SI, Ettle J, Hapfelmeier A, Steiger K, Specht K, Weichert W, Kiechle M, Klein E.

The Breast 49:101-107, 2020

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375593/

Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay.

Soliman H, Flake II DD, Magliocco A, Robson M, Schwartzberg L, Sharma P, Brown K, Wehnelt S, Kronenwett R, Gutin A, Lancaster J, Cuzick J, Gradishar W.

JCO Precis Oncol 2019 [Epub ahead of print]

https://ascopubs.org/doi/10.1200/PO.18.00361

Prognostic value of EndoPredict for invasive lobular carcinomas in the combined ABCSG-6/8 and TransATAC trials.

Sestak I, Filipits M, Buus R, Kronenwett R, Knauer M, Cuzick J, Dowsett M, Dubsky P.

Abstract: Ann Oncol. 30;2019 (suppl 3; abstr iii20).

https://oncologypro.esmo.org/Meeting-Resources/ESMO-Breast-Cancer-2019/Prognostic-value-of-endopredict-for-invasive-lobular-carcinomas-in-the-combined-ABCSG-6-8-and-TransATAC-trials

Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.

Filipits M, Dubsky P, Rudas M, Greil R, Balic M, Bago-Horvath Z, Singer C, Hlauschek D, Brown K, Bernhisel R, Kronenwett R, Lancaster J, Fitzal F, Gnant M.

Clin Cancer Res. 2019;25:3865-72.

https://www.ncbi.nlm.nih.gov/pubmed/?term=Prediction+of+Distant+Recurrence+using+EndoPredict+among+Women+with+ER%2B%2C+HER2-+Node-+Positive+and+Node-Negative+Breast+Cancer+Treated+with+Endocrine+Therapy+Only.

Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer.

Hannouf MB, Zaric GS, Blanchette P, Brezden-Masley C, Paulden M, McCabe C, Raphael J, Brackstone M.

Pharmacogenomics J. 2019 [Epub ahead of print]

https://www.ncbi.nlm.nih.gov/pubmed/?term=Cost-effectiveness+analysis+of+multigene+expression+profiling+assays+to+guide+adjuvant+therapy+decisions+in+women+with+invasive+early-stage+breast+cancer.

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.

Sestak I, Martin M, Dubsky P, Kronenwett R, Rojo F, Cuzick J, Filipits M, Ruiz A, Gradishar W, Soliman H, Schwartzberg L, Buus R, Hlauschek D, Rodriguez A, Gnant M.

Breast Cancer Res Treat. 2019; 176:377-86.

https://www.ncbi.nlm.nih.gov/pubmed/31041683

The impact of EndoPredict® on decision making with increasing oncological work experience: can overtreatment be avoided?

Thangarajah F, Eichler C, Fromme J, Malter W, Radosa JC, Ludwig S, Puppe J, Paepke S, Warm M.

Arch Gynecol Obstet. 2019;299:1437–42.

https://www.ncbi.nlm.nih.gov/pubmed/?term=The+impact+of+EndoPredict%C2%AE+on+decision+making+with+increasing+oncological+work+experience%3A+can+overtreatment+be+avoided%3F

RESCUE: REACHING FOR EVIDENCE-BASED CHEMOTHERAPY USE IN ENDOCRINE SENSITIVE BREAST CANCER, A prospective health care study on risk assessment by the clinicomolecular test EndoPredict® and long-term patient outcome in early luminal breast cancer.

Ettl J, Blohmer J-U, Denkert C, Keller M, Klein E, Kronenwett R, Neuser P, Paepke S, Schade-Brittinger C, Schnuppe K, Untch M, Wittenberg M, Kiechle M.

Poster: SABCS 2018; OT1-12-03.

https://cancerres.aacrjournals.org/content/79/4_Supplement/OT1-12-03

Change in therapeutic management after EndoPredict assay in a prospective decision impact study of Mexican premenopausal breast cancer patients.

Villarreal-Garza C, Deneken-Hernandez Z, Maffuz-Aziz A, Lopez-Martinez EA, Muñoz-Lozano JF, Barragan-Carrillo R, Peña-Curiel O, Moreno-Jaime B, Ramos-Elias P, Diaz H, Bautista-Piña V, Garcia-Garcia M, Mesa-Chavez F.

Poster: SABCS 2018; P2-08-54.

https://cancerres.aacrjournals.org/content/79/4_Supplement/P2-08-54

EndoPredict prognostic signature in pN1mi, estrogen receptor-positive breast cancer: analysis of the French national registry for molecular signatures.

Lacroix-Triki M, Arnould L, MacGrogan G, Penault-Llorca F, Haudebourg J, Tas P, Garnier A, Vincent-Salomon A, Miquel C, Lehmann-Che J, Callens C, Quillien V, Cayre A, Lamy PJ, Rouleau E, de Cremoux P.

Poster: SABCS 2018; P4-08-23.

https://cancerres.aacrjournals.org/content/79/4_Supplement/P4-08-23

First prospective outcome data for the clinico-molecular test EndoPredict® in hormone receptor positive, HER2-negative early breast cancer in clinical routine.

Ettl J, Anders KS, Hapfelmeier A, Paepke S, Noske A, Weichert W, Klein E, Kiechle M.

Poster: SABCS 2018; P4-08-11.

https://cancerres.aacrjournals.org/content/79/4_Supplement/P4-08-11

The impact of EndoPredict clinical score on chemotherapy recommendations in women with invasive ER+/HER2- breast cancer stratified as having moderate or poor prognosis by Nottingham Prognostic Index.

Mokbel K, Wazir U, Wazir A, Kasem A, Mokbel K.

Anticancer Res. 2018;38:4747-52.

https://www.ncbi.nlm.nih.gov/pubmed/3006144

Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinicomolecular predictor.

Loibl S, Weber K, Huober J, Krappmann K, Marmé F, Schem C, Engels K, Pfitzner BM, Kümmel S, Furlanetto J, Hartmann A, Darb-Esfahani S, Müller V, Staebler A, von Minckwitz G, Kronenwett R, Denkert C.

Clin Cancer Res. 2018;24:3358-65.

https://www.ncbi.nlm.nih.gov/pubmed/?term=Risk+assessment+after+neoadjuvant+chemotherapy+in+luminal+breast+cancer+using+a+clinicomolecular+predictor.

Predicting expected absolute chemotherapy treatment benefit in women with early-stage breast cancer using a 12-gene expression assay.

Gradishar W, Robson M, Flake II DD, Schwartzberg L, Sharma P, Soliman H, Magliocco A, Brown K, Wehnelt S, Gutin A, Kronenwett R, Lancaster J.

Abstract: J Clin Oncol 36, 2018 (suppl; abstr 525).

https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.525